Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: Incidence and clinical relevance

Blood

Volumn 101, Issue 7, 2003, Pages 2617-2619

  Greinacher, Andreas ^a   Eichler, Petra ^b   Albrecht, Dorothea ^b   Strobel, Ulrike ^b   Pötzsch, Bernd ^b   Eriksson, Bengt I ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESULFATOHIRUDIN; HIRUDIN ANTIBODY; IMMUNOGLOBULIN G; LEPIRUDIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; ANTICOAGULANT AGENT; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; RECOMBINANT PROTEIN;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIP SURGERY; HUMAN; IMMUNIZATION; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOSIS; TOTAL HIP PROSTHESIS; ANTICOAGULANT THERAPY; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HIP ARTHROPLASTY; IMMUNOLOGY; METHODOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; HIRUDIN THERAPY; HIRUDINS; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037769831     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1055     Document Type: Article

References (19)

1. Bichler J, Gemmerli R, Fritz H. Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons. Thromb Res. 1991;61:39-51.
2. Schlaeppi JM, Vekemans S, Rink H, Chang JY. Preparation of monoclonal antibodies to hirudin and hirudin peptides. Eur J Biochem. 1990;188:463-470.
3. Schlaeppi JM. Preparation of monoclonal antibodies to the thrombin/hirudin complex. Thromb Res. 1991;62:459-470.
4. Gygax D, Botta L, Ehrat M, et al. Immunoassays in monitoring biotechnological drugs. Ther Drug Monit. 1996;18:405-409.
5. Close P, Bichler J, Kerry R, et al. Weak allergenicity of recombinant hirudin CGP 39393 (Revasc) in immunocompetent volunteers: The European Hirudin in Thrombosis Group (HIT Group). Coron Art Dis. 1994;5:943-949.
6. Zoldhelyi P, Webster MW, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. Circulation. 1993;88:2015-2022.
7. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris: a multicenter randomized angiographic trial. Circulation. 1994;89:1557-1566.
8. Van den Bos AA, Deckers JW, Heyndrickxs GR, et al. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 1993;88:2058-2066.
9. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Circulation. 1997;96:769-777.
10. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients wlth acute myocardial ischaemia without ST elevation: a randomized trial. Lancet. 1999;353:429-438.
11. Eichler P, Greinacher A. Anti-hirudin antibodies induced by recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Ann Hematol. 1996;72(suppl 1):21.
12. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000;96:2373-2378.
13. Song XH, Huhle G, Wang LC, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation. 1999;100:1528-1532.
14. Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol. 1999;106:195-201.
15. Eriksson BI, Ekman S, Kaelebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347:635-639.
16. Eriksson BI, Wille-Jørgensen P, Kälebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Eng J Med. 1997;337:1329-1335.
17. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79:326-333.
18. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time. Thromb Hemost. 1997;77:920-925.
19. Huhle G, Liebe V, Hudek R, Heene DL. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife. Thromb Haemost. 2001;85:936-938.